Silence Therapeutics plc (NASDAQ:SLN – Get Free Report) was the target of a significant decrease in short interest during the month of July. As of July 15th, there was short interest totalling 560,700 shares, a decrease of 26.1% from the June 30th total of 759,200 shares. Based on an average daily volume of 157,700 shares, the short-interest ratio is presently 3.6 days.
Analyst Ratings Changes
SLN has been the subject of a number of analyst reports. Morgan Stanley upped their price objective on shares of Silence Therapeutics from $45.00 to $49.00 and gave the company an “overweight” rating in a research note on Friday, June 28th. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a research note on Thursday, June 27th. Finally, Chardan Capital lifted their price objective on shares of Silence Therapeutics from $42.00 to $55.00 and gave the stock a “buy” rating in a research report on Friday, June 28th.
View Our Latest Stock Report on Silence Therapeutics
Hedge Funds Weigh In On Silence Therapeutics
Silence Therapeutics Trading Down 0.1 %
NASDAQ SLN traded down $0.03 during trading on Friday, reaching $20.99. 355,353 shares of the company’s stock were exchanged, compared to its average volume of 214,903. Silence Therapeutics has a fifty-two week low of $4.88 and a fifty-two week high of $27.72. The company’s fifty day simple moving average is $20.35 and its 200-day simple moving average is $21.40.
Silence Therapeutics (NASDAQ:SLN – Get Free Report) last posted its quarterly earnings results on Thursday, May 16th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.18. Silence Therapeutics had a negative net margin of 131.44% and a negative return on equity of 79.90%. The business had revenue of $15.73 million during the quarter, compared to analysts’ expectations of $4.53 million. As a group, analysts predict that Silence Therapeutics will post -1.52 earnings per share for the current fiscal year.
About Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.
Further Reading
- Five stocks we like better than Silence Therapeutics
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Is Crypto Cool Again? What Stocks You Should Be Watching
- Most active stocks: Dollar volume vs share volume
- Why Call Options Volume for These 2 Stocks Spiked Together
- How Technical Indicators Can Help You Find Oversold Stocks
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.